Business Context and Reporting Period
Company: Spero Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 12, 2019
Event: Entry into a Material Definitive Agreement (Securities Purchase Agreement) with Novo Holdings A/S for a registered direct offering of common stock.
Key Financial Metrics
This filing does not report historical revenue, profit, cash flow, or margin data. It details a capital raise transaction with the following financial terms:
- Total Offering Size: Up to $10.0 million in aggregate.
- Initial Closing: 465,983 shares at $10.73 per share, generating approximately $5.0 million in gross proceeds.
- Second Closing: Up to an additional $5.0 million, priced based on the volume-weighted average price of the ten trading days preceding the closing date.
- Use of Proceeds: To advance the SPR720 therapeutic program.
- Debt and Liquidity: The filing text does not provide specific values for existing debt or liquidity positions.
Material Changes and Transaction Structure
The primary material change is the execution of a two-closing registered direct offering:
- Initial Closing: Expected on or about June 14, 2019, subject to customary conditions.
- Second Closing Trigger: The earlier of (i) the eleventh trading day following the public announcement of pharmacokinetic data from the lead-in cohort of the pivotal Phase 3 clinical trial of SPR994, or (ii) June 30, 2020.
- Condition Precedent: The Investor has no obligation to purchase shares in the second closing if the Company ceases all research and development of SPR720 prior to the data disclosure date.
- Dilution Cap: The Company will not issue shares that would require stockholder approval under Nasdaq Rule 5635; if the limit is reached, the Company will issue the maximum number of shares permissible without such approval.
Outlook, Risks, and Management Commentary
- Strategic Focus: Management intends to utilize net proceeds specifically for the SPR720 therapeutic program.
- Contingencies: The second tranche of funding is contingent on the continued development of SPR720 and the timing of SPR994 clinical data disclosure.
- Risks: The transaction is subject to customary closing conditions. The second closing is not guaranteed and depends on specific clinical milestones and the Company's continued R&D activities on SPR720.
- Unusual Items: The offering is being conducted directly to the Investor without a placement agent, underwriter, broker, or dealer.
Investor Verification Checklist
- Verify the exact closing date of the initial $5.0 million tranche (expected June 14, 2019).
- Monitor the public announcement date of pharmacokinetic data from the SPR994 Phase 3 trial lead-in cohort to determine the potential timing of the second closing.
- Confirm the Company's continued commitment to the SPR720 program to ensure the second closing condition is not triggered negatively.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific representations, warranties, and indemnification obligations.
- Check subsequent filings for the final share count issued in the second closing, as the price is variable based on market performance.